Table 1.
Clinical and demographic characteristics of Crohn’s disease patients treated with ustekinumab.
| n (%) | |
|---|---|
| Age (mean ± SD), years | 41 ± 14 |
| Gender | |
| Male | 41 (38.6) |
| Disease duration (mean ± SD), years | 12.2 ± 8 |
| Disease behavior | |
| B1 (inflammatory) | 41 (38) |
| B2 (stricturizing) | 33 (30.5) |
| B3 (penetrating) | 34 (31.5) |
| Disease location | |
| L1 (ileal) | 49 (45.4) |
| L2 (colonic) | 15 (13.8) |
| L3 (ileocolic) | 44 (40.8) |
| Perianal surgery | 7 (6.5) |
| Previous related Crohn’s disease surgery | |
| Ileocolic resection | 19 (18) |
| Hemicolectomy | 10 (9.4) |
| Small intestine resection | 8 (8) |
| Other | 10 (9.4) |
| None | 59 (55.6) |
| Background diseases | 35 (33) |
| Previous conventional therapy | |
| Immunomodulators | 45 (41.7) |
| Concomitant immunomodulators | 29 (26.9) |
| 5-ASA | 23 (21.3) |
| None | 11 (10.1) |
| Previous biological treatment | |
| One anti-TNF agent | 21 (19.4) |
| Two anti-TNF agents | 19 (17.5) |
| Anti-TNF and vedolizumab | 68 (63.0) |